As the world's largest drugmaker, Pfizer faces a lot of patent losses. Blockbusters like Lipitor, Effexor, and Viagra all lose exclusivity in the next three years. But after closing its huge acquisition of rival Wyeth in 2009, the company looks able to absorb the losses. Revenue and earnings showed modest gains for the year. Profits were mostly driven by acquisition savings, which Pfizer says will total $4 billion by 2012. But Wyeth also brings profitable biologic treatments, like the rheumatoid arthritis drug Enbrel and meningitis vaccine Prevnar, which should help Pfizer's bottom line in 2010.--S.C. |
| Key financials |
$ millions |
% change
from 2008 |
| Revenues |
50,009.0 |
3.5 |
| Profits |
8,635.0 |
6.6 |
| Assets |
212,949.0 |
— |
| Stockholders' equity |
90,014.0 |
— |
| Market value (3/26/2010) |
138,285.2 |
— |
| Profits as % of |
|
| Revenues |
17.3 |
| Assets |
4.1 |
| Stockholders' equity |
9.6 |
| Earnings per share |
|
| 2009 $ |
1.23 |
| % change from 2008 |
2.5 |
| 1999-2009 annual growth rate % |
4.1 |
| Total return to investors |
% |
| 2009 |
8.6 |
| 1999-2009 annual rate |
-2.6 |
|
Interactives
-
See how revenues and profits at America's 25 largest companies have risen and fallen over the past decade.
-
From a single store in 1962 to more than 4,300 outlets today, see how the biggest retailer has expanded.
|
